论文部分内容阅读
目的探讨肝动脉灌注栓塞术治疗肝癌的临床效果与安全性。方法选取50例肝癌患者作为研究组,所有患者行肝动脉灌注化疗后采取肿瘤血管末梢栓塞治疗;另选取经肝动脉灌注化疗的30例肝癌患者作为对照组,比较两组患者治疗后的瘤体客观反应率、甲胎蛋白(AFP)水平和生存率。结果研究组患者的生存率明显高于对照组,差异有统计学意义(P<0.05)。治疗后,研究组患者的AFP下降率和肿瘤缩小率明显高于对照组,差异有统计学意义(P<0.05)。研究组患者发热发生率为58.0%,消化道反应发生率为62.0%;对照组发热发生率为30.0%,消化道反应发生率为33.3%,研究组患者不良反应发生率明显高于对照组(P<0.05)。结论肝动脉灌注栓塞术治疗肝癌的疗效明显优于单纯肝动脉灌注化疗法,且不良反应较轻,值得临床推广应用。
Objective To investigate the clinical effect and safety of hepatic artery perfusion and embolization in the treatment of liver cancer. Methods Fifty patients with liver cancer were selected as study group. All patients underwent hepatic arterial infusion chemotherapy after embolization of tumor vessels. Thirty patients with hepatocellular carcinoma who underwent hepatic arterial infusion chemotherapy were selected as control group. After treatment, Objective response rate, AFP level and survival rate. Results The survival rate of the study group was significantly higher than that of the control group, the difference was statistically significant (P <0.05). After treatment, the study group AFP reduction rate and tumor reduction rate was significantly higher than the control group, the difference was statistically significant (P <0.05). In the study group, the incidence of fever was 58.0% and the incidence of digestive tract reaction was 62.0%. The incidence of fever in the control group was 30.0% and the incidence of gastrointestinal reactions was 33.3%. The incidence of adverse reactions in the study group was significantly higher than that in the control group P <0.05). Conclusions Hepatic arterial perfusion and embolization is superior to hepatic arterial perfusion chemotherapy alone in the treatment of hepatocellular carcinoma. The adverse reactions are mild and worthy of clinical application.